Metlife Inc MET
We take great care to ensure that the data presented and summarized in this overview for METLIFE INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MET
View all-
Vanguard Group Inc Valley Forge, PA58.3MShares$4.74 Billion0.09% of portfolio
-
Dodge & Cox San Francisco, CA54.7MShares$4.45 Billion2.73% of portfolio
-
Black Rock Inc. New York, NY47.5MShares$3.87 Billion0.08% of portfolio
-
State Street Corp Boston, MA26.7MShares$2.17 Billion0.09% of portfolio
-
Jpmorgan Chase & CO New York, NY19.9MShares$1.62 Billion0.13% of portfolio
-
Wellington Management Group LLP Boston, MA18.5MShares$1.51 Billion0.27% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD18.4MShares$1.5 Billion0.18% of portfolio
-
Geode Capital Management, LLC Boston, MA11.8MShares$958 Million0.08% of portfolio
-
Morgan Stanley New York, NY11.7MShares$955 Million0.07% of portfolio
-
Richard Pzena Pzena Investment Management LLC9.64MShares$784 Million2.63% of portfolio
Latest Institutional Activity in MET
Top Purchases
Top Sells
About MET
MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it provides fixed, indexed-linked, and variable annuities; and pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity reinsurance solutions; credit insurance products; and protection against long-term health care services. MetLife, Inc. was founded in 1863 and is headquartered in New York, New York.
Insider Transactions at MET
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 16
2024
|
Carla A Harris Director |
BUY
Grant, award, or other acquisition
|
Direct |
16
+0.23%
|
$1,312
$82.74 P/Share
|
Dec 16
2024
|
Edward J Kelly Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
232
+0.65%
|
$19,024
$82.74 P/Share
|
Dec 16
2024
|
Robert Glenn Hubbard Director |
BUY
Grant, award, or other acquisition
|
Direct |
579
+0.6%
|
$47,478
$82.74 P/Share
|
Dec 16
2024
|
Cheryl W Grise Director |
BUY
Grant, award, or other acquisition
|
Direct |
536
+0.62%
|
$43,952
$82.74 P/Share
|
Dec 16
2024
|
Diana Mckenzie Director |
BUY
Grant, award, or other acquisition
|
Direct |
132
+0.65%
|
$10,824
$82.74 P/Share
|
Dec 16
2024
|
Laura J Hay Director |
BUY
Grant, award, or other acquisition
|
Direct |
13
+0.64%
|
$1,066
$82.74 P/Share
|
Dec 16
2024
|
William E Kennard Director |
BUY
Grant, award, or other acquisition
|
Direct |
271
+0.65%
|
$22,222
$82.74 P/Share
|
Dec 16
2024
|
David L Herzog Director |
BUY
Grant, award, or other acquisition
|
Direct |
39
+0.15%
|
$3,198
$82.74 P/Share
|
Dec 16
2024
|
Jeh C. Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
33
+0.65%
|
$2,706
$82.74 P/Share
|
Dec 13
2024
|
Michel Khalaf President & CEO |
SELL
Open market or private sale
|
Direct |
20,926
-4.01%
|
$1,715,932
$82.84 P/Share
|
Dec 13
2024
|
Michel Khalaf President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
26,138
+4.77%
|
$1,176,210
$45.91 P/Share
|
Dec 13
2024
|
Marlene Debel EVP & Chief Risk Officer |
SELL
Open market or private sale
|
Direct |
22,810
-17.37%
|
$1,870,420
$82.88 P/Share
|
Dec 13
2024
|
Marlene Debel EVP & Chief Risk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,810
+8.3%
|
$912,400
$40.12 P/Share
|
Oct 01
2024
|
Robert Glenn Hubbard Director |
BUY
Grant, award, or other acquisition
|
Direct |
918
+0.95%
|
$74,358
$81.78 P/Share
|
Oct 01
2024
|
Diana Mckenzie Director |
BUY
Grant, award, or other acquisition
|
Direct |
535
+2.61%
|
$43,335
$81.78 P/Share
|
Oct 01
2024
|
Carlos M Gutierrez Director |
BUY
Grant, award, or other acquisition
|
Direct |
535
+2.35%
|
-
|
Oct 01
2024
|
Laura J Hay Director |
BUY
Grant, award, or other acquisition
|
Direct |
535
+21.02%
|
$43,335
$81.78 P/Share
|
Oct 01
2024
|
Denise M Morrison Director |
BUY
Grant, award, or other acquisition
|
Direct |
535
+1.69%
|
-
|
Oct 01
2024
|
David L Herzog Director |
BUY
Grant, award, or other acquisition
|
Direct |
535
+2.07%
|
-
|
Oct 01
2024
|
Cheryl W Grise Director |
BUY
Grant, award, or other acquisition
|
Direct |
535
+0.62%
|
$43,335
$81.78 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 611K shares |
---|---|
Exercise of conversion of derivative security | 74.1K shares |
Payment of exercise price or tax liability | 281K shares |
---|---|
Open market or private sale | 95.2K shares |